# Sunitinib

## Sutent 12.5mg

##### 臨採

| TAH Drug Code      | OSUT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of GI stromal tumor after disease progression on or intolerance to imatinib mesylate. Treatment of advanced or metastatic renal cell carcinoma (clear cell carcinoma in pathology).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | [Gastrointestinal Stromal Tumor (GIST) and Advanced Renal Cell Carcinoma (RCC)] 50 mg orally with or without food once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2). [Pancreatic neuroendocrine tumors (pNET)] 37.5 mg orally with or without food once daily continuously without a scheduled off-treatment period. [Adjuvant Treatment of RCC] 50 mg orally with or without food once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Pregnancy. Women of childbearing potential should avoid becoming pregnant while receiving treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Fatigue, asthenia, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspensia, abdominal pain, constipation, hypertension, rash, hand-foot syndrome, skin discoloration, altered taste, anorexia & bleeding. Potentially serious adverse reactions of LV dysfunction, QT interval prolongation, hemorrhage, hypertension & adrenal dysfunction. Dermatologic: Discoloration of skin, Yellow (GIST, 30%; MRCC, 19% ), Dry skin (MRCC, 18% ), Rash (GIST, 14%; MRCC, 27% ) Endocrine metabolic: Hypothyroidism (GIST, 4% to 36%; MRCC, 3% ) Gastrointestinal: Abdominal pain (MRCC, 22% ), Constipation (GIST, 20%; MRCC, 16% ), Diarrhea (GIST, 40%; MRCC, 58% ), Increased serum lipase level (GIST, 25%; MRCC, 52% ), Indigestion (MRCC, 28% ), Inflammatory disease of mucous membrane (GIST, 29%; MRCC, 43% ), Loss of appetite (GIST, 33%; MRCC, 38% ), Nausea (MRCC, 49% ), Pain of oral cavity structure (GIST, 6%; MRCC, 10% ), Taste sense altered (GIST, 21%; MRCC, 44% ), Vomiting (MRCC, 28% ) Hematologic: Anemia (GIST, 26%; MRCC, 71% ), Bleeding (GIST, 18%; MRCC, 30% ), Leukopenia (MRCC, 78% ), Lymphocytopenia (GIST, 38%; MRCC, 59% ), Neutropenic disorder (GIST, 53%; MRCC, 72% ) Hepatic: Liver function tests abnormal (GIST, 10% to 39%; MRCC, 13% to 56% ) Neurologic: Asthenia (GIST, 22%; MRCC, 21% ) Renal: Increased uric acid level (MRCC, 41% ) |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

